These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 17425479

  • 21. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC, Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, Cooper D, Lazzarin A, Kohlbrenner VM, Dohnanyi C, Sabo J, Mayers D.
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [Abstract] [Full Text] [Related]

  • 22. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A, Moyle G.
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [Abstract] [Full Text] [Related]

  • 23. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [Abstract] [Full Text] [Related]

  • 24. Drug interactions of tipranavir, a new HIV protease inhibitor.
    Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V.
    Drug Metab Lett; 2007 Jan; 1(1):81-4. PubMed ID: 19356024
    [Abstract] [Full Text] [Related]

  • 25. Tipranavir: a protease inhibitor for HIV salvage therapy.
    Dong BJ, Cocohoba JM.
    Ann Pharmacother; 2006 Jan; 40(7-8):1311-21. PubMed ID: 16788094
    [Abstract] [Full Text] [Related]

  • 26. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
    Walmsley SL, Cotte L, Rusconi S, Ward DJ, Hicks CB, Meier U, Valdez H, Boucher CA.
    AIDS; 2007 Oct 18; 21(16):2245-8. PubMed ID: 18090054
    [Abstract] [Full Text] [Related]

  • 27. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
    Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.
    BMC Infect Dis; 2009 Sep 14; 9():154. PubMed ID: 19751502
    [Abstract] [Full Text] [Related]

  • 28. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
    Temesgen Z, Feinberg J.
    Clin Infect Dis; 2007 Sep 15; 45(6):761-9. PubMed ID: 17712762
    [Abstract] [Full Text] [Related]

  • 29. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT.
    AIDS Clin Care; 2006 Aug 15; 18(8):72. PubMed ID: 16906669
    [No Abstract] [Full Text] [Related]

  • 30. Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.
    Antoniou T, Raboud JM, Diong C, Su D, Dewhurst N, Buckley V, Kovacs C, Rachlis A, Brunetta J, Smith G, Gough K, Fletcher D, Loutfy MR.
    J Int Assoc Physicians AIDS Care (Chic); 2010 Aug 15; 9(6):382-9. PubMed ID: 21138833
    [Abstract] [Full Text] [Related]

  • 31. Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
    Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.
    Int J STD AIDS; 2011 Nov 15; 22(11):617-20. PubMed ID: 22096044
    [Abstract] [Full Text] [Related]

  • 32. [Viral resistance and genetic barrier of atazanavir].
    Mendoza CD, Garrido C, Treviño A, Anta L, Poveda E, Soriano V.
    Enferm Infecc Microbiol Clin; 2008 Dec 15; 26 Suppl 17():28-33. PubMed ID: 20116614
    [Abstract] [Full Text] [Related]

  • 33. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R.
    AIDS; 2008 Nov 12; 22(17):2313-21. PubMed ID: 18981770
    [Abstract] [Full Text] [Related]

  • 34. Tipranavir.
    Temesgen Z, Cainelli F, Vento S.
    Drugs Today (Barc); 2005 Nov 12; 41(11):711-20. PubMed ID: 16395412
    [Abstract] [Full Text] [Related]

  • 35. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
    Allavena C, Flandre P, Pugliese P, Valantin MA, Poizot-Martin I, Cabié A, Melliez H, Cuzin L, Duvivier C, Dellamonica P, Raffi F, Dat'aids Group.
    Scand J Infect Dis; 2012 Jan 12; 44(1):37-43. PubMed ID: 21851330
    [Abstract] [Full Text] [Related]

  • 36. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005 Jan 12; 17(1):4-5. PubMed ID: 17225315
    [No Abstract] [Full Text] [Related]

  • 37. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
    Naeger LK, Struble KA.
    AIDS; 2007 Jan 11; 21(2):179-85. PubMed ID: 17197808
    [Abstract] [Full Text] [Related]

  • 38. New protease inhibitor offers clinicians hope for better salvage therapy.
    Murphy MJ.
    HIV Clin; 2006 Jan 11; 18(1):1-3. PubMed ID: 16838417
    [No Abstract] [Full Text] [Related]

  • 39. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
    Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW, Tarpley G.
    AIDS; 2000 Sep 08; 14(13):1943-8. PubMed ID: 10997398
    [Abstract] [Full Text] [Related]

  • 40. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M.
    J Antimicrob Chemother; 2007 Dec 08; 60(6):1195-205. PubMed ID: 17890281
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.